# Safety and Efficacy of MP-214 in Patients With Schizophrenia

> **NCT01625000** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 512 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MP-214 3mg
- **DRUG:** MP-214 6mg
- **DRUG:** MP-214 9mg
- **DRUG:** Risperidone 4mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01625000
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-08
- **Final completion:** 2015-10
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625000, "Safety and Efficacy of MP-214 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01625000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*